Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension

Atherosclerosis Supplements

Volumn 14, Issue 1, 2013, Pages 203-211

  Dandel, Michael ^a   Wallukat, Gerd ^b   Englert, Angela ^a   Hetzer, Roland ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

1 autoantibodies; Antibodies; Dilated cardiomyopathy; Endothelin A receptor autoantibodies; Immunoadsorption; Pulmonary hypertension

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; AUTOANTIBODY; BETA 1 ADRENERGIC RECEPTOR; ENDOTHELIN A RECEPTOR; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; FEMALE; HEART FUNCTION; HUMAN; IMMUNOADSORPTION; MALE; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

ABSORPTION; ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; CARDIOMYOPATHY, DILATED; HUMANS; HYPERTENSION, PULMONARY; IMMUNOSORBENT TECHNIQUES; IMMUNOSORBENTS; RECEPTOR, ENDOTHELIN A; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, BETA-1; TREATMENT OUTCOME;

EID: 84872873050     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2012.10.029     Document Type: Article

References (80)

1. Maron B.J., Towbin J.A., Thieme G., et al. Contemporary definitions and classification of cardiomyopathies: an American Heart Association Scientific Statement. Circulation 2006, 113:1807-1816.
2. Lappé J.M., Pelfrey C.M., Tang W.W.H. Recent insights into the role of autoimmunity in idiopathic dilated cardiomyopathy. J Card Fail 2008, 14(6):521-530.
3. Anderson J.L., Carlquist J.F., Hammond E.H. Deficient natural killer cell activity in patients with idiopathic dilated cardiomyopathy. Lancet 1982, 2:1124-1127.
4. Limas C.J., Goldenberg I.F., Limas C. Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy: correlation with disease severity and cardiac antibodies. Circulation 1995, 91:631-634.
5. Gerli R., Rambotti P., Spinozzi F., et al. Immunologic studies of peripheral blood from patients with idiopathic dilated cardiomyopathy. Am Heart J 1986, 112:350-355.
6. Schulze K., Becker B.F., Schauer R., Schultheiss H.P. Antibodies to ADP-ATP carrier - an autoantigen in myocarditis and dilated cardiomyopathy - impair cardiac function. Circulation 1990, 81:959-969.
7. Fu L.X., Magnusson Y., Bergh C.H., et al. Location of functional autoimmune epitope on muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1993, 91(5):1964-1968.
8. Wallukat G., Wollenberger A., Morwinski R., et al. Anti-β1-adrenoceptor antibodies with chronotropic activity from serum of patients with dilated cardionmyopathy: mapping of epitopes in the first and second extra- cellular loops. J Mol Cell Cardiol 1995, 27(1):397-406.
9. Caforio A.L., Mahon N.J., Tona F., McKenna W.J. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenic and clinical significance. Eur J Heart Fail 2002, 4:411-417.
10. Dörfel W.V., Felix S.B., Wallukat G., et al. Short term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 1997, 95:1994-1997.
11. Matsui S., Fu M.L., Katsuda S., et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol 1997, 29:641-655.
12. Müller J., Wallukat G., Dandel M., et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000, 101(4):385-391.
13. Felix S.B., Staudt A., Dörffel W.V. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three month results from a randomized study. J Am Coll Cardiol 2000, 35(6):1590-1598.
14. Knebel F., Böhm M., Staudt A., et al. Reduction of morbidity by immunadsorption therapy in patients with dilated cardiomyopathy. Int J Cardiol 2004, 97(3):517-520.
15. Felix S.B., Staudt A., Landsberger M. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorbtion. J Am Coll Cardiol 2002, 39(4):646-652.
16. Doesch A.O., Konstandin M., Celik S. Effects of protein A immunoadsorption in patients with advanced chronic dilated cardiomyopathy. J Clin Apher 2009, 24:141-149.
17. D'Alonzo G., Bart R., Ayres S., et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
18. Farber H.W., Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004, 351:1655-1665.
19. Wallukat G., Dandel M., Müller J., et al. Agonistic autoantibodies against the endothelin-1 ETA and α-1adrenergic receptor in sera of patients with idiopathic pulmonary arterial hypertension. Circulation 2007, 116(16 Suppl.):II-322.
20. 1-adrenergic and endothelin-1 receptors in pulmonary arterial hypertension. Circulation 2008, 118(18 Suppl. 2):S1072.
21. Sampietro T., Neglia D., Bionda A., et al. Inflammatory markers and serum lipids in idiopathic dilated cardiomyopathy. Am J Cardiol 2005, 96:1718-1720.
22. Yoshikawa T., Baba A., Nagatomo Y. Autoimmune mechanisms underlying dilated cardiomyopathy. Circ J 2009, 73:602-607.
23. Noutsias M., Pauschinger M., Schultheiss H., Kh U. Phenotype characterization in dilated cardiomyopathy - diagnostic significance of T lymphocytes and macrophages in inflammatory cardiomyopathy. Med Sci Monit 2002, 8:CR478-CR487.
24. Baba A., Yoshikawa T., Ogawa S. Autoantibodies against sarcolemal Na-K-ATPase: possible upstream targets of arrhythmias and sudden deaths in patients with dilated cadiomyopathy. J Am Coll Cardiol 2002, 40:1153-1159.
25. Omerovic E., Bollano E., Andersson B., et al. Induction of cardiomyopathy in severe combined immuno-deficiency mice by transfer of lymphocytes from patients with idiopathic dilated cardiomyopathy. Autoimmunity 2000, 32:271-280.
26. Konstadoulakis M.M., Krombouzou H., Tsiamis H., et al. Clinical significance of antibodies against tropomyosin, actin and myosin in patients with dilated cardiomyopathy. J Clin Lab Immunol 1993, 40:61-67.
27. Baba A., Yoshikawa T., Fukuda Y., et al. Autoantibodies against M2-muscarinic acetylcholine receptors: new upstreams targets in atrial fibrillation in patients with dilated cardiomyopathy. Eur Heart J 2004, 25:1108-1115.
28. Lauer B., Schannwell M., Kuhl U., et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2000, 35:11-18.
29. Wallukat G., Wollenberger A. Effects of serum gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic β-adrenergic function in cultured rat heart myocytes. Biochim Biomed Acta 1987, 78:634-639.
30. Gavin J.E., Hemric M.E., Kosanke S.D., et al. Induction of myocarditis and valvulitis in Lewis rats by different epitopes of cardiac myosin and its implications in rheumatic carditis. Am J Pathol 2002, 160:297-306.
31. Matsui S., Fu M.L., Hayase M., et al. Transfer of immune components from rabbit autoimmune cardio - myopathy into severe combined immunodeficiency (SCID) mice induces cardiomyopathic changes. Autoimmunity 2006, 39(2):121-128.
32. Jahns R., Boivin V., Hein L., et al. Direct evidence for beta-1 adrenergic receptor directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004, 113:1419-1429.
33. Cunningham M.W., Hall N.K., Krisher K.K., et al. A study of antigroup A streptococcal monoclonal antibodies cross-reactive with myosin. J Immunol 1986, 136:293-298.
34. Caforio A.L., Grazini M.M., Mann M.J., et al. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major antigens in dilated cardiomyopathy. Circulation 1992, 85:1734-1742.
35. Li Y., Heuser J.S., Cunningham L.C., et al. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol 2006, 177:8234-8240.
36. Staudt Y., Mobini R., Fu M., et al. Beta-1-adrenoceptor autoantibodies induce apoptosis in adult isolated cardiomyocytes. Eur J Pharmacol 2003, 466:1-6.
37. Horwich T.B., Patel J., MacLellan W.R., et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction and increased mortality rates in advanced heart failure. Circulation 2003, 108:833-838.
38. Groser S., Andrassy M., Buss S.J., et al. Cardiac troponin I but not cardiac troponin T induces severe auto-immune inflammation in the myocardium. Circulation 2006, 114:1693-1702.
39. Shmilowich H., Danon A., Binah O., et al. Autoantibodies to cardiac troponin I in patients with idiopathic dilated and ischemic cardiomyopathy. Int J Cardiol 2007, 117:198-203.
40. 1-adrenergic receptors induces early after-depolarization and decreases in K-channel density in rabbits. J Am Coll Cardiol 2004, 43:1090-1100.
41. Jahns R., Boivin V., Siegmund C., et al. Autoantibodies activating human beta adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999, 99:649-654.
42. 1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2001, 37:418-424.
43. Störk S., Boivin V., Horf R., et al. Stimulating autoantibodies directed against beta-1 adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 2006, 152:697-704.
44. Müller J., Wallukat G., Weng Y., et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation 1997, 96:542-549.
45. Dandel M., Weng Y., Siniawski H., et al. Prediction of cardiac stability after weaning from ventricular assist devices in patients with idiopathic dilated cardiomyopathy. Circulation 2008, 118(Suppl. 1):S94-S105.
46. Goodwin J.F. Mechanisms in cardiomyopathies. J Mol Cell Cardiol 1985, 17(Suppl. 2):5-9.
47. Maekawa Y., Ouzounian M., Opavsky M.A., Liu P.P. Connecting the missing link between dilated cardiomyopathy and viral myocarditis: virus, cytoskeleton, and innate immunity. Circulation 2007, 115:5-8.
48. 1-adrenoceptor antibodies in dilated cardiomyopathy and Chagas' disease. Autoimmunity 2008, 41(6):429-433.
49. Jane-wit D., Altuntas C.Z., Johnson J.M., et al. β1-adrenergic receptor autoantibodies mediate dilated cardio- myopathy by agonistic induced apoptosis. Circulation 2007, 116:399-410.
50. Wallukat G., Müller J., Podlowski S., et al. Agonist like beta-adrenergic antibodies in heart failure. Am J Cardiol 1999, 83:75H-79H.
51. Christ T., Wettwer E., Dobrew D., et al. Autoantibodies against the beta-1 adrenoceptor prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol 2001, 33:1515-1525.
52. Nicolls M.R., Taraseviciene-Stewart L., Rai P.R., et al. Autoimmunity in pulmonary hypertension: a perspective. Eur Respir J 2005, 26:1110-1118.
53. Tamby M.C., Chanseaud Y., Humbert M., et al. Anti-endothelial cell autoantibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 2005, 60:765-772.
54. Tamby M.C., Humbert M., Guilpain P., et al. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J 2006, 28:799-807.
55. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin 1 in lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328:1732-1739.
56. Salvi S.S. α-1-adrenergic hypothesis for pulmonary hypertension. Cest 1999, 115:1708-1719.
57. James M.F.M., Hickman R., Janicki P., et al. Early effects of total hepatectomy on hemodynamic state and organ uptake of catecholamines in the pig. Brit J Anaesth 1996, 76:713-720.
58. Bevan J.A., Oriowo M.A., Bevan R.D. Physiological variation in α-adrenoreceptor-mediated arterial sensitivity: relation to agonist affinity. Science 1986, 234:196-197.
59. Chen Y.F., Oparil S. Endothelial dysfunction in the pulmonary vascular bed. Am J Med Sci 2000, 320(4):223-232.
60. Rich S.R., McLaughlin V.V. Endothelin receptor blockers in cardiovascular disease. Circulation 2003, 108:2184-2190.
61. MacLean M.R. Endothelin-1: a mediator of pulmonary hypertension?. Pulm Pharmacol Ther 1998, 11:125-132.
62. Love M.P., Haynes W.G., Gray G.A., et al. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996, 94:2131-2137.
63. Nootens M., Kaufmann E., Rector T., et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995, 26:1581-1585.
64. Wallukat G., Reinke P., Dörffel W.V., et al. Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int J Cardiol 1996, 54:91-95.
65. Schimke I., Müller J., Priem F. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy: one year after immunoglobulin adsorption. J Am Coll Cardiol 2001, 38:178-183.
66. Mobini R., Staudt A., Felix S.B., et al. Hemodynamic improvement and removal of autoantibodies against beta-1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun 2003, 20:345-350.
67. Staudt A., Dörr M., Staud Y., et al. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption. Am Heart J 2005, 150:729-736.
68. Staudt A., Hummel A., Ruppert J., et al. Immunoadsorption in dilated cardiomyopahy: 6 months results from a randomized study. Am Heart J 2006, 152. 712.el-6.
69. Herda L.R., Trimpert C., Nauke U., et al. Effects of immunoadsorption and subsequent immunoglobulin G substitution on cardiopulmonary exercise capacity in patients with dilated cardiomyopathy. Am Heart J 2010, 159(5):809-816.
70. Dörfel W.V., Wallukat G., Dörfel Y. Immunoadsorption in dilated cardiomyopathy, a 3 year follow-up. Int J Cardiol 2004, 97(3):529-534.
71. Dandel M., Wallukat G., Englert A. Efficacy of immunoadsorption as bridge-to-transplant therapy in patients with idiopathic dilated cardiomyopathy and evidence of beta-1 adrenoceptor autoantibodies. J Heart Lung Transplant 2010, 29(2):163-164.
72. Staudt A., Herda R., Trimpert C. Fcγ-receptor IIa polymorphism and the role of immunoadsorption in cardiac dysfunction in patients with dilated cardiomyopathy. Clin Pharamcol Ther 2010, 87:452-458.
73. Dandel M., Wallukat G., Englert A., et al. Are the therapeutic benefits of extracorporeal immunoglobulin adsorption in beta-1 adrenoceptor autoantibody positive patients with dilated cardiomyopathy indeed related to the removal of these antibodies?. Circulation 2010, 122(Suppl.):A10319.
74. 1 adrenoceptor autoantibodies in the pathogenesis of dilated cardiomyopathy. Immunobiology 2012, 217(5):511-520.
75. Felix S., Staudt A. Immunoadsorption as treatment option in dilated cardiomyopathy. Autoimmunity 2008, 41(6):484-489.
76. Ikeda U., Kasai H., Izawa A., et al. Immunoadsorbtion therapy for patients with dilated cardiomyopathy and heart failure. Curr Cardiol Rev 2008, 4:219-222.
77. Staudt A., Schaper F., Stangl V., et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 2001, 103:2681-2686.
78. Cooper L.T., Belohlavek M., Korinek J., et al. A pilot study to asses the use of protein A immunoadsorption for chronic dilated cardiomyopathy. J Clin Apher 2007, 22:210-214.
79. Dandel M., Wallukat G., Lehmkuhl H., Englert A., Hetzer R. Functional autoantibodies against G-protein coupled receptors in sera of patients with pulmonary arterial hypertension: potential involvement in the pathogenesis of the disease. J Am Coll Cardiol 2009, 53(10 Suppl. A):A454.
80. Dandel M., Wallukat G., Englert A., Lehmkuhl H., Hetzer R. Autoantibodies against endothelin-1 receptors are involved in the pathogenesis of pulmonary arterial hypertension. Circulation 2009, 120(18 Suppl. 2):S1134.